Journal of hepatology
Elsevier BV · Clinical Medicine · ISSN 0168-8278, 1600-0641
- Impact (2-yr)
- 2.6
- h-index
- 382
- Open access
- 21%
- Works
- 57.4K
- Papers this month
- 35
Rebuilt
Moved this week
Latest in Journal of hepatology
Newest first · last 60 days
Elevated left ventricular mass index (LVMI) predicts morbidity and mortality in children with cirrhosis, with specific thresholds independently associated with adverse outcomes.
STRIDE treatment shows a 14.4% objective response rate and a 19.8% incidence of Grade 3/4 PRAEs within 6 months in poor-prognosis unresectable hepatocellular carcinoma patients.
Spatial and single-cell transcriptomics reveal the CD226-NECTIN2 T cell-cholangiocyte interaction as a key feature in bile duct inflammation in NOD.c3c4 mice and human liver disease.
Resmetirom improves MASH resolution and fibrosis in non-cirrhotic patients regardless of high-risk MASH genotypes, with effects consistent across genetic profiles.
Integrating systemic therapy at earlier stages of liver cancer shows promising but uncertain benefits, with data supporting combination approaches in hepatocellular carcinoma and biliary tract cancers.
- Open access
Liver transplantation remains the most effective curative approach for primary liver cancers, with transplant eligibility now based on dynamic assessments of survival and tumor biology.
Immune checkpoint inhibitor-based combinations are now the standard first-line systemic therapy for advanced hepatocellular carcinoma, showing improved survival and response rates.
- Open access
AI-driven multimodal models outperform single-modality approaches in predicting recurrence and survival in liver cancer patients.
- Open access
Liver cancer surveillance lacks randomized trial evidence, with most positive results being false positives in low-prevalence populations, limiting support beyond hepatology.
- Open access
- 1 cites
Targeted therapies for intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements show meaningful response rates and durable disease control.
Advances in surgical planning and molecular understanding are expanding the resectability of liver cancers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
- 1 cites
Primary liver cancer incidence and mortality increased by over 55% globally from 2000 to 2023, reversing earlier declines around 2020.
- Open access
Locoregional therapies in cholangiocarcinoma show 3-year overall survival rates ranging from 17% to 50% depending on the modality and disease site.
Blood-based biomarkers show promise for liver cancer but require further validation before widespread clinical use.
Advances in liver cancer imaging now enable biological characterization and personalized treatment guidance beyond traditional detection methods.
- Open access
- 1 cites
Liver transplantation significantly improves one-year survival in patients with ACLF-2 and ACLF-3 compared to those who are declined, with 88% mortality in ACLF-3 patients declined for transplant.
Resmetirom and semaglutide are recommended for treating non-cirrhotic MASH with fibrosis stages 2-3, with specific patient profiles guiding therapy choice.
Track Journal of hepatology in JClub
Browse JClub
Journals this month
- bioRxiv6131
- medRxiv1703
- PNAS447
- Sci Adv354
- JAMA262
- Environ Res230
- BMJ182
- Environ Pollution165
- Nat Commun161
- Science141
- Nature138
- Lancet128
- Cell Rep120
- NEJM119
- mBio107
- Plant Cell Environ107
- Curr Biol106
- J Exp Bot106
Topics moving, week to 23 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Bacteriophages and microbial interactions5
- Gut microbiota and health5
- Genomics and Phylogenetic Studies4
- Cancer Genomics and Diagnostics4
- Cancer Immunotherapy and Biomarkers4
- Alzheimer's disease research and treatments3
- Inflammatory Bowel Disease3
- Influenza Virus Research Studies3